Literature DB >> 15993875

Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease.

Kandiah Umapathysivam1, John J Hopwood, Peter J Meikle.   

Abstract

BACKGROUND: Pompe disease is an autosomal recessive disorder of glycogen metabolism resulting from a deficiency of acid alpha-glucosidase. Pompe disease can present within a broad clinical spectrum, from the severe infantile to the attenuated adult onset phenotypes. Early diagnosis, in the form of newborn screening has been proposed. However, in the absence of clinical symptoms, prediction of disease severity and progression will be critical to provide appropriate management and treatment of affected individuals.
METHODS: We have used sensitive immune-assays to measure levels of acid alpha-glucosidase protein and activity in cultured skin fibroblasts and a new glycogen assay to specifically determine the lysosomal accumulation of glycogen in the same cells. These markers were assessed for their ability to predict age of onset.
RESULTS: Acid alpha-glucosidase activity and specific activity as well as lysosomal glycogen showed significant correlations with age of onset, with acid alpha-glucosidase activity having the highest Spearman correlation coefficient (0.887, p<0.001). Lysosomal glycogen accumulated only in cells from infantile and juvenile patients but not from adult-onset patients. However, cells from adult-onset patients had relatively low cytoplasmic glycogen compared to control individuals and other forms of the disease.
CONCLUSION: Acid-alpha-glucosidase activity and specific activity, and lysosomal glycogen content are useful predictors of age of onset in Pompe disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15993875     DOI: 10.1016/j.cccn.2005.05.025

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  13 in total

1.  Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.

Authors:  Na Lin; Jingyu Huang; Sara Violante; Joseph J Orsini; Michele Caggana; Erin E Hughes; Colleen Stevens; Lisa DiAntonio; Hsuan Chieh Liao; Xinying Hong; Farideh Ghomashchi; Arun Babu Kumar; Hui Zhou; Ruth Kornreich; Melissa Wasserstein; Michael H Gelb; Chunli Yu
Journal:  Clin Chem       Date:  2017-02-14       Impact factor: 8.327

2.  Correction of glycogenosis type 2 by muscle-specific lentiviral vector.

Authors:  Emmanuel Richard; Gaëlle Douillard-Guilloux; Lionel Batista; Catherine Caillaud
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-09-23       Impact factor: 2.416

Review 3.  Current and Future Treatments for Lysosomal Storage Disorders.

Authors:  David P W Rastall; Andrea Amalfitano
Journal:  Curr Treat Options Neurol       Date:  2017-11-04       Impact factor: 3.598

4.  A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.

Authors:  Andreas Herzog; Ralf Hartung; Arnold J J Reuser; Pia Hermanns; Heiko Runz; Nesrin Karabul; Seyfullah Gökce; Joachim Pohlenz; Christoph Kampmann; Christina Lampe; Michael Beck; Eugen Mengel
Journal:  Orphanet J Rare Dis       Date:  2012-06-07       Impact factor: 4.123

5.  Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts.

Authors:  Monica Cardone; Caterina Porto; Antonietta Tarallo; Mariella Vicinanza; Barbara Rossi; Elena Polishchuk; Francesca Donaudy; Generoso Andria; Maria Antonietta De Matteis; Giancarlo Parenti
Journal:  Pathogenetics       Date:  2008-12-01

Review 6.  Recent advances in gene therapy for lysosomal storage disorders.

Authors:  David Pw Rastall; Andrea Amalfitano
Journal:  Appl Clin Genet       Date:  2015-06-24

7.  Splice modulating antisense oligonucleotides restore some acid-alpha-glucosidase activity in cells derived from patients with late-onset Pompe disease.

Authors:  May Thandar Aung-Htut; Kristin A Ham; Michel Tchan; Russell Johnsen; Frederick J Schnell; Sue Fletcher; Steve D Wilton
Journal:  Sci Rep       Date:  2020-04-21       Impact factor: 4.379

8.  Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease.

Authors:  Michael Beck
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423

9.  A review of treatment of Pompe disease in infants.

Authors:  Yin-Hsiu Chien; Wuh-Liang Hwu
Journal:  Biologics       Date:  2007-09

10.  Distinct disease phenotypes linked to different combinations of GAA mutations in a large late-onset GSDII sibship.

Authors:  Simone Sampaolo; Teresa Esposito; Olimpia Farina; Daniela Formicola; Daria Diodato; Fernando Gianfrancesco; Federica Cipullo; Gaetana Cremone; Mario Cirillo; Luca Del Viscovo; Antonio Toscano; Corrado Angelini; Giuseppe Di Iorio
Journal:  Orphanet J Rare Dis       Date:  2013-10-10       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.